This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2023 · cache
25 of 69 declarations
No purchase is recorded at Clever Leaves Holdings Inc.: the 29 sales (28 with an amount) total EUR 210,225, but the median is only EUR 1,361. One trade stands out: Kyle Detwiler, chief executive officer, sold EUR 130,629 on December 30, 2021. Andres Fajardo, filed as chief executive officer and also as president, sold EUR 21,331 on January 17, 2023 and EUR 12,593 on December 30, 2021.
Eleven insiders filed 69 times between December 22, 2020 and March 12, 2024, with a peak of 24 in 2022. Henry R. Hague III, chief financial officer, Julian Wilches, chief regulatory officer, and Andres Fajardo sign 12 each, of which 8, 7 and 7 sales. Kyle Detwiler has 8, 2 of them sales, and Gary M. Julien, a director, 5, one of them a sale. The record holds 40 grants.
Filings are published a median of 2 days after the trade. The Nasdaq-listed Health Care company has no filing over the last twelve months.
| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2023 | 17.4 m USD | -17.9 m USD | -11.42 USD | 10-K |
| Dec 2022 | 16.4 m USD | -66.2 m USD | -51.70 USD | 10-K |
| Dec 2021 | 15.4 m USD | -45.7 m USD | -1.78 USD | 10-K |
| Dec 2020 | 12.1 m USD | -25.9 m USD | -3.34 USD | 10-K |
| Dec 2019 | 7.8 m USD | -39.5 m USD | n.d. | 10-K/A |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.